Wolfe Research upgraded Alnylam (ALNY) to Peer Perform from Underperform and removed the firm’s prior $368 price target The company “surprised” with its ability to find new patients, says the analyst, who adds that the stock’s “lofty valuation still bothers us,” but the firm is “owning up to our mistaken Underperform rating,” noting that shares have performed well since November of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY: